NCAM1
Neural cell adhesion molecule 1
As of the edition of 20 October 2026, NCAM1 (neural cell adhesion molecule 1, UniProt P13591) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13591
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 7
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Immune system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Hormones
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lorvotuzumab mertansine | Went quiet | Phase 2 | none listed |
| DXC006 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| ImmunoGen | Route A |
The other 1 company at NCAM1
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at NCAM1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.